NATCO PHARMA LTD. (NATCOPHARM)

NSE: ₹918.70
BSE: ₹918.90
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earning call Transcript for the concall held on May 29, 2026

2026-06-04 14:53:24
Announcement under Regulation 30 (LODR)-Press Release / Media Release

NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection

2026-06-03 11:14:03
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication of Annual Audited Financial Results for the Quarter and Year ended March 31, 2026

2026-05-30 12:22:32
2026-05-30 12:18:31
2026-05-29 15:34:05
Audited Financial Results For The Quarte And Year Ended 31St March, 2026

Audited Financial Results for the quarter and year ended 31st March, 2026

2026-05-29 14:28:34
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March, 2026

Audited Financial Results for the quarter and year ended 31st March, 2026

2026-05-29 14:16:46
Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report for FY 2025-26

2026-05-26 16:21:46
2026-05-21 12:23:34
Board Meeting Intimation for Considering Audited Financial Results For The Financial Year Ended 31St March, 2026

considering Audited Financial Results for the Financial year ended 31st March, 2026

2026-05-18 16:38:10

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 1,048.30 930.50 625.30 964.80 1,236.90 1,292.60 407.60 1,157.40 1,192.70 1,264.30 528.80 608.80
YOY Revenue Growth % 30.11% 165.02% 51.4% 23.5% 17.99% 38.91% -34.82% 19.96% -3.57% -2.19% 29.74% -47.4%
Other Income 14.60 24.70 29.50 35.90 39.80 51.40 168.00 62.10 59.60 93.30 55.30 72.90
Total Income 1,062.90 955.20 654.80 1,000.70 1,276.70 1,344.00 575.60 1,219.50 1,252.30 1,357.60 584.10 681.70
Total Expenses + 587.70 531.20 431.20 568.20 518.70 547.10 425.30 698.70 709.40 771.60 458.90 571.70
Cost of Materials Consumed 136.10 166.60 92.20 127.60 151.30 143.20 72.70 169.00 180.60 174.90 135.20 102.80
Employee Benefit Expense 119.20 106.80 103.90 125.00 120.20 132.80 123.60 138.70 143.50 178.60 136.50 133.10
Other Expenses 248.40 200.50 172.40 281.20 208.10 213.30 184.30 235.90 325.80 378.70 160.30 259.50
Operating Profit 460.60 399.30 194.10 396.60 718.20 745.50 -17.70 458.70 483.30 492.70 69.90 37.10
OPM % 43.9% 42.9% 31% 41.1% 58.1% 57.7% -4.3% 39.6% 40.5% 39% 13.2% 6.1%
Profit Before Tax + 475.20 424.00 223.60 432.50 758.00 796.90 150.30 520.80 542.90 586.00 125.20 110.00
Tax Expense 69.90 63.80 31.60 83.40 121.70 135.80 25.40 92.70 78.80 85.10 18.30 -99.60
Tax % 14.7% 15% 14.1% 19.3% 16.1% 17% 16.9% 17.8% 14.5% 14.5% 14.6% -90.5%
Profit After Tax 405.30 360.20 192.00 349.10 636.30 661.10 124.90 428.10 464.10 500.90 106.90 209.60
EPS (Basic) 22.43 20.11 10.72 19.49 35.53 36.91 6.97 23.90 25.91 27.97 5.97 11.70

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Revenue from Operations 3,594.60 4,094.50 3,568.90 2,351.00 1,767.80 1,653.50 1,790.20
YOY Revenue Growth % -12.21% 14.73% 51.8% 32.99% 6.91% -7.64% -
Other Income 281.10 321.30 104.70 85.50 94.60 101.10 123.80
Total Income 3,875.70 4,415.80 3,673.60 2,436.50 1,862.40 1,754.60 1,914.00
Total Expenses + 2,511.60 2,189.80 2,118.30 1,665.80 1,706.50 1,362.40 1,144.20
Cost of Materials Consumed 593.50 536.20 522.50 475.30 519.20 372.90 329.00
Employee Benefit Expense 591.70 515.30 454.90 425.70 410.10 380.00 356.10
Other Expenses 1,124.30 841.60 902.50 550.90 610.10 355.90 459.10
Operating Profit 1,083.00 1,904.70 1,450.60 685.20 61.30 291.10 646.00
OPM % 30.1% 46.5% 40.6% 29.1% 3.5% 17.6% 36.1%
Profit Before Exceptional 1,364.10 2,226.00 1,555.30 770.70 155.90 392.20 583.10
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 1,364.10 2,226.00 1,555.30 770.70 155.90 392.20 583.10
Tax Expense 82.60 375.60 248.70 133.60 16.80 82.70 108.60
Tax % 6.1% 16.9% 16% 17.3% 10.8% 21.1% 18.6%
Profit After Tax 1,281.50 1,850.40 1,306.60 637.10 139.10 309.50 474.50
EPS (Basic) 71.55 103.31 72.79 34.90 7.63 16.99 26.08

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
ASSETS
Non-Current Assets + 5,967.40 3,581.90 3,143.60 2,893.20 2,799.80 2,591.50 0.00
Property, Plant & Equipment 2,519.70 2,409.60 2,273.20 2,218.20 2,158.10 1,996.50 0.00
Capital Work in Progress 293.40 225.30 133.90 62.80 128.70 223.40 0.00
Non-Current Investments 98.30 74.70 95.90 87.30 86.30 119.40 0.00
Goodwill 0.00 0.00 0.00 0.00 16.10 0.00 0.00
Other Intangible Assets 95.60 107.20 13.50 15.60 0.00 9.40 0.00
Current Assets + 4,320.00 4,688.00 3,410.40 2,494.70 2,178.20 2,161.00 0.00
Inventories 723.60 642.10 596.90 616.00 697.70 769.20 0.00
Trade Receivables 759.60 1,178.20 1,076.60 793.10 575.60 399.80 0.00
Cash and Cash Equivalents 11.50 11.20 5.50 6.90 5.90 5.10 0.00
Current Investments 573.50 290.00 163.90 139.90 119.60 34.60 0.00
LIABILITIES & EQUITY
Total Equity 8,552.60 7,333.90 5,592.30 4,702.00 4,191.90 4,091.10 0.00
Equity Share Capital 35.80 35.80 35.80 36.50 36.50 36.50 0.00
Other Equity 8,516.80 7,298.10 5,556.50 4,665.50 4,155.40 4,054.60 0.00
Non-Current Liabilities 168.40 71.40 76.10 116.90 134.90 142.90 0.00
Current Liabilities 1,566.40 864.60 885.60 569.00 651.20 518.50 0.00
Total Liabilities 1,734.80 936.00 961.70 685.90 786.10 661.40 0.00

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Cash from Operating Activities 1,776.40 1,662.00 1,196.40 799.80 57.70 183.50 0.00
Cash from Investing Activities -2,078.20 -1,443.90 -960.50 -436.60 -92.50 -3.20 0.00
Cash from Financing Activities 302.10 -212.40 -237.30 -345.40 35.60 -183.10 0.00
Net Increase/Decrease in Cash 0.30 5.70 -1.40 17.80 0.80 -2.80 0.00